Ultragenyx’s experimental therapy GTX-102 for Angelman syndrome failed in a Phase 3 trial, showing no benefit versus sham treatment. The company said it is now weighing “significant” cost cuts as it recalibrates after the setback, which erodes hopes that the program could drive profitability for the biotech in a rare-disease portfolio. The Phase 3 failure also follows earlier investor enthusiasm based on positive early trials and a prior FDA approval for another ultrarare indication (Genglycos). Ultragenyx’s next steps are expected to focus on clinical and financial prioritization rather than expansion. For the sector, the read-through is that even highly selective, mechanism-led neurodevelopment programs face steep evidentiary demands in confirmatory settings, and runway planning remains a critical variable after large, milestone-heavy trials miss endpoints.